Business
Business Journalist Velvet-Belle Templeman speaks to Paul Hopper, the Executive Chairman of SUDA Pharmaceuticals Ltd (ASX: SUD). The company, a leader in oro-mucosal drug delivery, announced that it has entered into a fully-funded feasibility study and option agreement with Spanish pharmaceutical company Laboratorios Ordesa, S.L., (Ordesa). Hopper discusses product commercialisation, exciting developments in their Cancer project, the role of the company's new CEO as well as insights for shareholders in the next 6 months.